{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"68.3","upperLimit":"85.5","value":"77.8"},{"groupId":"OG001","lowerLimit":"68.1","upperLimit":"85.1","value":"77.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"102"}],"units":"Participants"}],"description":"MRR defined as the percentage of participants achieving a best response of response of CR, defined as normal serum IgM levels, disappearance of monoclonal protein by immunofixation, and negative cryoglobulinemia if cryoglobulinemia was positive at baseline, VGPR, defined as ≥90% reduction in serum IgM level from baseline or normal serum IgM values or partial response (PR) defined as ≥50% reduction of serum IgM from baseline.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants diagnosed with WM with mutated MYD88 gene received 420 mg ibrutinib once daily orally until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor","id":"OG000","title":"Arm A: Ibrutinib"},{"description":"Participants diagnosed with WM with mutated MYD88 gene received 160 mg zanubrutinib twice daily orally until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor","id":"OG001","title":"Arm B: Zanubrutinib"}],"paramType":"NUMBER","populationDescription":"ITT Analysis Set","reportingStatus":"POSTED","timeFrame":"Up to approximately 2 years and 7 months","title":"Percentage of Participants Achieving Major Response Rate (MRR) as Assessed by IRC","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}